ATP11A

Across TCGA pan-cancer cohorts, ATP11A mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of ATP11A’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where ATP11A mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types ATP11A is over-expressed in tumor, although a few such as LSCC show the opposite, repressed pattern.

LSCC, CCRCC, and PDAC are the cancer types where ATP11A tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ATP11A mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Female	II,III,IV	−1.113	<.001	9	view →
CCRCC	Male	III,IV	+0.725	<.001	7	view →
PDAC	Female	II,III,IV	+0.623	<.001	6	view →
HNSC	All	All	+0.247	<.001	6	view →
COAD	All	All	+0.651	.002	5	view →
LUAD	Female	All	+0.259	.013	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

ATP11A–LSCC

Open the LSCC breakdown →